S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:VRAY

ViewRay (VRAY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.03
$0.65
52-Week Range
N/A
Volume
108.50 million shs
Average Volume
7.51 million shs
Market Capitalization
$4.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.54

ViewRay MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
∞ Upside
$2.54 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

VRAY stock logo

About ViewRay Stock (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

VRAY Stock News Headlines

VRAY Jan 2025 2.000 call
VRAY Jan 2025 0.500 put
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
VRAY Jan 2025 0.500 call
VRAY Jan 2025 3.000 put
ViewRay Inc VRAYQ
NUBURU Appoints Brian Knaley as new CEO
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
ViewRay Inc (6L9.BE)
Why ViewRay Stock Hit A New 52-Week Low Today
Why Is ViewRay (VRAY) Stock Down 69% Today?
ViewRay® Files Voluntary Chapter 11 Petitions
ViewRay (NASDAQ: VRAY)
Viewray (VRAY) Receives a Hold from Stifel Nicolaus
B.Riley Financial downgrades Viewray (VRAY) to a Hold
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2023
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:VRAY
Employees
295
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$2.54
High Stock Price Target
$8.00
Low Stock Price Target
$1.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-107,330,000.00
Net Margins
-104.30%
Pretax Margin
-104.30%

Debt

Sales & Book Value

Annual Sales
$105.86 million
Book Value
$0.45 per share

Miscellaneous

Free Float
178,817,000
Market Cap
$4.59 million
Optionable
Optionable
Beta
0.81

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Scott William DrakeMr. Scott William Drake (Age 55)
    Pres, CEO & Director
    Comp: $1.8M
  • Mr. Robert S. McCormack J.D. (Age 56)
    Chief Legal Officer
    Comp: $692.36k
  • Dr. James F. Dempsey Ph.D. (Age 52)
    Founder & Chief Scientific Officer
  • Mr. William P. Burke (Age 54)
    Exec. VP & CFO
  • Drew Hill
    Sr. VP of Operations & Devel.
  • Matt Harrison
    Director of Investor Relations
  • Karen Hackstaff
    VP of Marketing
  • Mr. Robert Michael Fuchs (Age 56)
    Chief HR Officer
  • Dr. Martin Fuss M.D.
    Ph.D., Chief Medical Officer
  • Mr. Paul Ziegler Jr. (Age 49)
    J.D., Exec. VP & Chief Commercial Officer

VRAY Stock Analysis - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings
or view top-rated stocks.

What is ViewRay's stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for ViewRay's stock. Their VRAY share price targets range from $1.00 to $8.00. On average, they predict the company's share price to reach $2.54 in the next twelve months.
View analysts price targets for VRAY
or view top-rated stocks among Wall Street analysts.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) announced its quarterly earnings data on Monday, February, 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to the consensus estimate of $34.65 million. ViewRay had a negative net margin of 104.30% and a negative trailing twelve-month return on equity of 120.48%. The company's revenue was up 70.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.16) EPS.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

ViewRay (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Does ViewRay have any subsidiaries?
The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
This page (NASDAQ:VRAY) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners